Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Meniere Disease - Overview
Meniere Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Meniere Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Meniere Disease - Companies Involved in Therapeutics Development
IntraBio Ltd
Orbis Biosciences Inc
Otonomy Inc
Quark Pharmaceuticals Inc
Sound Pharmaceuticals Inc
Synphora AB
Meniere Disease - Drug Profiles
betamethasone valerate ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ebselen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IB-2000s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latanoprost - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QPHL-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Meniere Disease - Dormant Projects
Meniere Disease - Product Development Milestones
Featured News & Press Releases
Sep 18, 2019: FDA grants Fast Track Desigtion for SPI-1005 in the treatment of Meniere’s Disease
Jun 25, 2019: Sound Pharmaceuticals announces positive topline results from the SPI-1005 Phase 2b Meniere’s Disease clinical trial
Mar 20, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere’s Disease clinical trial
Mar 06, 2019: Sound Pharmaceuticals announces completion of patient enrollment in the Phase 2b Meniere’s Disease clinical trial
Feb 06, 2019: Otonomy announces presentation on OTIVIDEX at Association for Research in Otolaryngology Annual Meeting
Oct 02, 2018: Otonomy announces OTIVIDEX data presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
Jul 26, 2018: Otonomy Initiates Phase 3 Clinical Trial of OTIVIDEX in Meniere Disease
Nov 08, 2017: Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX in Patients with M?ni?re’s Disease
Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease
Aug 30, 2017: Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX in Patients with Menieres Disease
Jun 27, 2017: Sound Pharmaceuticals completes enrollment on Meniere’s Disease clinical trial
Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere’s Disease
Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use
Jan 19, 2017: Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss
Aug 01, 2016: Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Meniere Disease Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Meniere Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Meniere Disease, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Meniere Disease - Pipeline by IntraBio Ltd, H1 2020
Meniere Disease - Pipeline by Orbis Biosciences Inc, H1 2020
Meniere Disease - Pipeline by Otonomy Inc, H1 2020
Meniere Disease - Pipeline by Quark Pharmaceuticals Inc, H1 2020
Meniere Disease - Pipeline by Sound Pharmaceuticals Inc, H1 2020
Meniere Disease - Pipeline by Synphora AB, H1 2020
Meniere Disease - Dormant Projects, H1 2020